EUVIMEDEUVIMED entdecken
Crossref

Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis

Ryo Morikawa, Toshimitsu Fujii, Akiko Tamura, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Kazuo Ohtsuka, Ryuichi Okamoto

Intestinal Research · 10.08.2026

DOI: 10.5217/ir.2025.00338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, online erschienen am 10.08.2026. Verfasst von Ryo Morikawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is a chronic inflammatory bowel disease resulting from inappropriate immune responses and is characterized by diarrhea and bloody stools. Currently, numerous biologics and small-molecule agents have been developed and have improved outcomes in patients with UC. 1 Interleukin-23 (IL-23), a heterodimeric cytokine composed of p19 and p40 subunits, plays an important role in inflammatory bowel disease pathogenesis. 2 Risankizumab (RZB) is a monoclonal antibody targeting the IL-23 p19 subunit, and its efficacy in treating UC has been demonstrated in a phase 3 clinical trial. 3 However, unlike the phase 3 trial for Crohn’s disease, 4,5 the trial for UC did not examine patients with prior exposure to ustekinumab (UST). Consequently, the efficacy of RZB in such patients remains unclear. Therefore, this study aimed to evaluate the short-term real-world efficacy of RZB in patients with UC previously treated with UST at our institution. This retrospective cohort study included patients with UC who were previously exposed to UST and were initiated on RZB therapy between July 2024 and August 2025

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan. tfujii.gast@tmd.ac.jp.

Zitieren

APA

Morikawa, R., Fujii, T., Tamura, A., Kawamoto, A., Hibiya, S., Takenaka, K., Shimizu, H., Ohtsuka, K., & Okamoto, R. (2026). Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis. Intestinal Research. https://doi.org/10.5217/ir.2025.00338

Vancouver

Morikawa R, Fujii T, Tamura A, Kawamoto A, Hibiya S, Takenaka K, et al. Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis. Intestinal Research. 2026. doi:10.5217/ir.2025.00338

BibTeX
@article{Morikawa2026,
  author = {Morikawa, Ryo and Fujii, Toshimitsu and Tamura, Akiko and Kawamoto, Ami and Hibiya, Shuji and Takenaka, Kento and Shimizu, Hiromichi and Ohtsuka, Kazuo and Okamoto, Ryuichi},
  title = {Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis},
  journal = {Intestinal Research},
  year = {2026},
  doi = {10.5217/ir.2025.00338}
}
Kostenlos starten →